Skip to Main Content
Contribute Try STAT+ Today

Artificial intelligence is the hot new thing in drug discovery and development. AstraZeneca, Pfizer, and Merck have all relied on machine learning to advance their research. Bristol-Myers Squibb and Boston-based Concerto HealthAI established a new partnership in March. And Relay Therapeutics raised an astonishing $400 million series C round to support its efforts to use AI techniques to understand the way proteins bend and twist and create new drugs.

But if artificial intelligence programs are actually going to make an impact, they’re going to need a lot of data — and high quality data is hard to come by. Currently available data sets aren’t ideal for machine learning, and relying on that data might even set certain algorithms down the wrong path.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Comments are closed.